Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report
- 1 July 2026
- journal article
- case report
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 26 (8) , 1049-1053
Abstract
Introduction/Background: Cholangiocarcinoma (CC) is a rare, aggressive cancer of the bile ducts with limited treatment advancements over recent decades. The five-year survival rate for CC remains low, around 10%, and even lower for advanced cases. Case Presentation: This case report discusses a 46-year-old woman with metastatic CC who achieved remarkable progression-free survival with regorafenib, a multikinase inhibitor typi-cally used in other cancers. After multiple lines of treatment, regorafenib was given as a 7th-line therapy. Despite initial intolerance requiring dose reduction, the patient achieved 22 months of progression-free survival (PFS) with stable disease and partial regression in some areas. Her response to regorafenib significantly exceeded typical outcomes in the literature, where PFS generally ranges from 3 to 4 months. This improvement may be attributed to an FGFR2 mutation identified via next-generation sequencing, which regorafenib may effec-tively target. Conclusion: This case suggests that patients with FGFR2 mutations might benefit from regorafenib, warranting further studies to explore this associationAs can be applied as a promising target gene to develop drug resistance and remedial efficacy.Keywords
This publication has 11 references indexed in Scilit:
- Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trialAnnals of Oncology, 2020
- A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancerCancer, 2020
- Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 studyThe Lancet Oncology, 2019
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinomaCancer, 2018
- FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitroMolecular Oncology, 2018
- Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?Cancer Management and Research, 2018
- Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsAnnals of Oncology, 2013
- Fibroblast growth factor signalling: from development to cancerNature Reviews Cancer, 2010
- Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and PancreasGastroenterology, 2009
- CholangiocarcinomaThe Lancet, 2005